Eli Lilly and Company: Obesity trials

The registry lists 117 Obesity studies with Eli Lilly and Company as lead sponsor. 32 are open to participants now and 29 have results posted.

Phase 1 40Phase 2 21Phase 3 51Phase 4 4No phase 1(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesActive, not recruitingNCT06075667Phase 3
• A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesCompletedNCT06047548Phase 3
• A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or ObeseCompletedNCT06039826Phase 1
• A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and ObesityActive, not recruitingNCT06037252Phase 2
• A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the KneeCompletedNCT05931367Phase 3
• A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightCompletedNCT05929079Phase 3
• A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightCompletedNCT05929066Phase 3
• A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseCompletedNCT05882045Phase 3
• A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskCompletedNCT05803421Phase 3
• A Study of LY3305677 in Participants With Obesity Or OverweightCompletedNCT05623839Phase 1
• A Study of LY3457263 in Obese ParticipantsCompletedNCT05582096Phase 1
• A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityActive, not recruitingNCT05556512Phase 3
• A Study of LY3437943 in Chinese Participants With Obesity Or OverweightCompletedNCT05548231Phase 1
• A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesCompletedNCT05536804Phase 2
• A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese ParticipantsCompletedNCT05445232Phase 1
• A Study of LY3541105 in Healthy and Overweight ParticipantsCompletedNCT05380323Phase 1
• A Study of LY3841136 in Healthy and Overweight ParticipantsCompletedNCT05295940Phase 1